GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » PS Ratio

Durata Therapeutics (FRA:DTA) PS Ratio : 64.66 (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Durata Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Durata Therapeutics's share price is €18.88. Durata Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2014 was €0.29. Hence, Durata Therapeutics's PS Ratio for today is 64.66.

Warning Sign:

Durata Therapeutics Inc stock P/S Ratio (=63.58) is close to 1-year high of 63.58

The historical rank and industry rank for Durata Therapeutics's PS Ratio or its related term are showing as below:

FRA:DTA' s PS Ratio Range Over the Past 10 Years
Min: 34.61   Med: 62.11   Max: 63.58
Current: 63.58

During the past 3 years, Durata Therapeutics's highest PS Ratio was 63.58. The lowest was 34.61. And the median was 62.11.

FRA:DTA's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.03 vs FRA:DTA: 63.58

Durata Therapeutics's Revenue per Sharefor the three months ended in Sep. 2014 was €0.29. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2014 was €0.29.

Back to Basics: PS Ratio


Durata Therapeutics PS Ratio Historical Data

The historical data trend for Durata Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durata Therapeutics PS Ratio Chart

Durata Therapeutics Annual Data
Trend Dec11 Dec12 Dec13
PS Ratio
- - -

Durata Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 34.32

Competitive Comparison of Durata Therapeutics's PS Ratio

For the Biotechnology subindustry, Durata Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durata Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Durata Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Durata Therapeutics's PS Ratio falls into.



Durata Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Durata Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=18.88/0.292
=64.66

Durata Therapeutics's Share Price of today is €18.88.
Durata Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.29.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Durata Therapeutics  (FRA:DTA) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Durata Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Durata Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Durata Therapeutics (FRA:DTA) Business Description

Traded in Other Exchanges
N/A
Address
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Durata Therapeutics (FRA:DTA) Headlines

No Headlines